Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)
Subscribe To Our Newsletter & Stay Updated